Therapeutical Class：Fluoroquinolones, inhibition of DNA gyrase and prevention of DNA replication

Indication：Active against G(+), G(-) organisms. Most strains of streptococci are only moderately susceptible. Active against Mycoplasma, Chlamydia trachomatis, Legionella and Mycobacterium tuberculosis. Ureoplasma urealyticum and anaerobic bacteria are usually resistant.

Administraton：

Adults: PO 250-750 mg q12h. IV 200-400 mg q12h, 400 mg q8h in severe cases. Children: PO, IV. 20-30 mg/kg/day in 2 divided doses.

Renal impairment: Oral: Ccr 30-50 ml/min,250-500 mg q12h;

Ccr 5-29 ml/min, 250-500 mg q18h.

Dialysis: 250-500 mg q24h. IV: Ccr 5-29 ml/min, 200-400 mg q18-24h.

Adverse Effect：Nausea, vomiting, cramping, headache (1-10%), dizziness, photosensitivity (<1%), tendon inflammation (<1%), fatigue, eosinophilia, fever, rash (1-10%), crystalluria, arthropathy, diarrhea (1-10%), tinnitus, elevated AST, ALT and decreased neutrophil counts, seizures.

Contraindication：Hypersensitivity to other quinolones.

Pregnancy Risk：C

Supply：Ciproxin XE “Ciproxin” FC Tab 250mg（速博新膜衣錠 Bayer）＜02030＞

Ciproxin XE “Ciproxin” Inf Sol 200mg/100ml（速博新針劑 Bayer）＜10436＞